Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).

[1]  Sanjiv J. Shah,et al.  Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. , 2008, Journal of the American College of Cardiology.

[2]  J. Gore,et al.  Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery. , 2007, International journal of cardiology.

[3]  C. Cannon,et al.  Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. , 2006, Critical pathways in cardiology.

[4]  N. Smedira,et al.  Occurrence and Risk Factors for Reintervention After Coronary Artery Bypass Grafting , 2006, Circulation.

[5]  R. Califf,et al.  A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 , 2006, Circulation.

[6]  A. Skene,et al.  Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. , 2005, The New England journal of medicine.

[7]  R. Platt,et al.  Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. , 2005, Journal of the American College of Cardiology.

[8]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[9]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[10]  V. Hasselblad,et al.  Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. , 2004, JAMA.

[11]  S. Snapinn,et al.  Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. , 2004, The American journal of cardiology.

[12]  Jerome Sacks,et al.  Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. , 2002, Journal of the American College of Cardiology.

[13]  R. Califf,et al.  Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting: Results From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial , 2002, Circulation.

[14]  W. O’Neill,et al.  Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. , 2001, Journal of the American College of Cardiology.

[15]  R. Califf,et al.  The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. , 2001, American heart journal.

[16]  B. Gersh,et al.  Comparison of percutaneous interventions for unstable angina pectoris in patients with and without previous coronary artery bypass grafting. , 2000, The American journal of cardiology.

[17]  B. Hoogwerf,et al.  Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial , 2000 .

[18]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[19]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[20]  M. Leon,et al.  Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. , 1997, The New England journal of medicine.

[21]  E. Jones,et al.  Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. , 1997, Circulation.

[22]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[23]  P. Serruys,et al.  Long-term clinical outcome after stent implantation in saphenous vein grafts. , 1996, Journal of the American College of Cardiology.

[24]  P. Stone,et al.  Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). , 1996, The American journal of cardiology.

[25]  R H Selzer,et al.  Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. , 1996, Circulation.

[26]  S. Azen,et al.  Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. , 1990, JAMA.

[27]  D. Waters,et al.  Long-term prognosis after myocardial infarction in patients with previous coronary artery bypass surgery. , 1988, Journal of the American College of Cardiology.

[28]  R. L. Johnson,et al.  The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. , 1987, Controlled clinical trials.

[29]  D. Waters,et al.  Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris. , 1986, The American journal of cardiology.